Evidence map›Paper›PMID 29328452›Full record

ArticleOncology reports2018

HIF‑1α‑induced upregulation of lncRNA UCA1 promotes cell growth in osteosarcoma by inactivating the PTEN/AKT signaling pathway.

Tengfei Li, Yang Xiao, Tunsheng Huang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Tengfei LiDepartment of Chinese and Western Μedicine Οrthopedics of 31 Ward, Loudi Central Hospital, Loudi, Hunan 417000, P.R. China.
Yang XiaoDepartment of Chinese and Western Μedicine Οrthopedics of 31 Ward, Loudi Central Hospital, Loudi, Hunan 417000, P.R. China.
Tunsheng HuangDepartment of Chinese and Western Μedicine Οrthopedics of 31 Ward, Loudi Central Hospital, Loudi, Hunan 417000, P.R. China.
Loudi Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidence indicates that long non‑coding RNAs (lncRNAs) play an important role in multiple biological processes including cell growth, differentiation, proliferation and invasion. Urothelial carcinoma associated 1 (UCA1) is a highly conserved nuclear ncRNA and a key regulator of cell proliferation and apoptosis in several types of cancers. However, its role in osteosarcoma progression is not well known. In the present study, we aimed to determine the biological role of UCA1 in osteosarcoma progression. RT‑qPCR analysis showed that UCA1 expression was significantly increased in osteosarcoma cell lines and promoted cell growth in osteosarcoma. We then sought to determine the mechanism underlying the upregulation of UCA1 in osteosarcoma. Luciferase reporter assay and chromatin immunoprecipitation assay suggested that lncRNA UCA1 was induced by HIF‑1α and HIF‑1α interacts with the HIF‑1α response element in the promoter region of UCA1. In addition, the gain- and loss-of-functional assay showed that HIF‑1α promoted osteosarcoma cell growth through inducing the UCA1 expression level. More importantly, Cignal Signal Transduction Reporter Array and western blot assay showed that lncRNA UCA1 inactivated the PTEN/AKT signaling pathway. Finally, we observed that HIF‑1α induced cell growth through the UCA1/PTEN/AKT signaling pathway. To conclude, our integrated approach demonstrates that UCA1 confers a tumor promoter function by promoting cell proliferation and silencing of the PTEN/AKT signaling pathway in osteosarcoma. Thus, UCA1 can serve as a promising therapeutic target for osteosarcoma patients.

Indexed as

Cell ProliferationApoptosisBiomarkers, TumorBone NeoplasmsGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitOsteosarcomaProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseRNA, Long NoncodingSignal TransductionTranscriptional ActivationTumor Cells, CulturedUp-RegulationAKT1 protein, humanBiomarkers, TumorHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, humanRNA, Long NoncodingUCA1 RNA, human

Identifiers

PMID29328452
PMCPMC5802028
OpenAlexW2782405197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.